Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study

NCT07270263 is registered in ClinicalTrials.gov with Medical University of Gdansk as lead sponsor.

NCT NCT07270263
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07270263 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies: A Prospective Randomized Study
Lead sponsor
Medical University of Gdansk
Phase
Not applicable
Overall status
Recruiting
Start date
November 22, 2024
Completion date
December 31, 2026
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hematologic malignacies, leukemia, lymphoma, multiple myeloma (mm), lymphoma, large b-cell, diffuse (dlbcl), lymphoma, pe - pulmonary embolism, venous thromboembolic disease, vte (venous thromboembolism)